Faceptor

DRUG2 trials

Sponsors

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Conditions

Breast Cancer FemaleBreast Cancer MetastaticBreast Cancer Recurrent

Phase 1

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

CompletedNCT05301530

Nanogen Pharmaceutical Biotechnology Joint Stock CompanyBreast Cancer Female, Breast Cancer Metastatic, Breast Cancer Recurrent

Start: 2019-05-27End: 2021-02-19Updated: 2022-03-29

Phase 3

Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients

CompletedNCT05301010

Nanogen Pharmaceutical Biotechnology Joint Stock CompanyBreast Cancer Female, Breast Cancer Metastatic, Breast Cancer Recurrent

Start: 2018-02-02End: 2021-02-19Updated: 2023-02-27